证券代码：838810 证券简称：春光药装 公告编号：2023-041 辽宁春光制药装备股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 辽宁春光制药装备股份有限公司（以下简称"公司"）于 2023 年 5 月 10 日接待了 1 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2023 年 5 月 10 日 调研地点：辽宁春光制药装备股份有限公司 调研形式：现场调研 调研机构：广发证券股份有限公司 上市公司接待人员：董事会秘书 金勇 二、 调研的主要问题及公司回复概要 问题 1：公司凭借哪些能力实现了入选国家第四批专精特新"小巨人"企业？ 回答：在公司董事长毕春光先生带领下，目前公司已建立起一支较为稳定的 长期从事包装装备研发的团队，公司拥有辽宁省制药包装装备专业技术创新中 心、辽宁省医药食品包装装备产学研联盟、辽宁春光制药装备股份有限公司企业 技术中心、辽宁省智能包装装备工程研究中心、辽宁春光制药装备股份有限公司 专家工作站——五大技术创 ...

证券代码：838810 证券简称：春光药装 公告编号：2023-039 一、 说明会类型 辽宁春光制药装备股份有限公司（以下简称"公司"）于 2023 年 4 月 24 日 在北京证券交易所指定信息披露平台（http://www.bse.cn/）发布了《辽宁春光制 药装备股份有限公司 2022 年年度报告》（公告编号：2023-026），为方便广大投 资者更深入了解公司 2022 年经营业绩的具体情况，加强与投资者的互动交流， 公司拟召开 2022 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 4 日。 （二）会议召开地点 公司定于 2023 年 5 月 4 日（周四）15:00-17:00 在全景网举办 2022 年年度 报告业绩说明会，本次年报业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年报业绩说明会。 三、 参加人员 公司董事长：毕春光先生 公司总经理：边境女士 公司财务负责人：陈蕾女士 公司董事会秘书：金勇先生 公司保荐代表人：孙贝洋先生 辽宁春光制药装备股份有限公司 20 ...

Financial Performance - Operating revenue for the first quarter of 2023 was CNY 51,045,814.36, representing a year-on-year growth of 27.85%[10] - Net profit attributable to shareholders for the first quarter of 2023 was CNY 7,684,095.67, up 33.17% from the same period last year[10] - The net profit margin for the first quarter of 2023 was approximately 15.08%, reflecting improved profitability[10] - Total operating revenue for Q1 2023 reached ¥51,045,814.36, a significant increase from ¥39,927,026.95 in Q1 2022, representing a growth of approximately 28.1%[54] - Net profit for Q1 2023 was ¥7,684,095.67, up from ¥5,770,196.79 in Q1 2022, reflecting a growth of approximately 33.3%[56] - The total comprehensive income amounted to 7,982,611.80, compared to 5,770,196.79 in the previous year[60] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 442,797,535.41, an increase of 2.03% compared to the end of 2022[10] - Total liabilities amounted to CNY 153,059,579.47, slightly up from CNY 152,040,697.45, reflecting a marginal increase of 0.67%[48] - Shareholders' equity reached CNY 289,737,955.94, compared to CNY 281,951,875.27, marking an increase of approximately 2.78%[48] - Current assets totaled CNY 357,241,080.85, an increase from CNY 347,271,541.50, reflecting a growth of about 2.83%[46] - Total assets at the end of the reporting period were ¥412,018,697.07, up from ¥403,055,478.26, reflecting a growth of about 2.4%[52] Cash Flow - The net cash flow from operating activities decreased by 128.79% to CNY -2,818,387.26 compared to the previous year[11] - Cash inflow from operating activities was 41,317,783.97, down from 45,804,214.16 in the same period last year, representing a decrease of approximately 9.7%[61] - Total cash outflow from operating activities was 44,136,171.23, compared to 36,013,677.83 in the previous year, indicating an increase of about 22.6%[63] - Cash and cash equivalents decreased to CNY 152,264,619.45 from CNY 178,406,927.66, a decline of approximately 14.65%[46] Expenses - Research and development expenses for the first quarter of 2023 amounted to CNY 136,420.00, a decrease of 35.48% year-on-year[14] - Sales expenses increased by 187.72% to CNY 4,516,200.00 due to increased marketing activities[14] - Total operating costs for Q1 2023 were ¥42,403,116.82, compared to ¥33,655,772.00 in Q1 2022, indicating an increase of about 26.0%[55] - Research and development expenses for Q1 2023 were ¥1,364,229.54, down from ¥2,114,302.53 in Q1 2022, indicating a reduction of approximately 35.3%[55] Shareholder Information - The total number of unrestricted shares decreased from 22,753,221 to 22,691,646, representing a change of -61,575 shares, which is a decrease of approximately 0.27%[22] - The total number of restricted shares increased from 45,746,779 to 45,808,354, representing a change of 61,575 shares, which is an increase of approximately 0.13%[22] - The largest shareholder, Bi Chunguang, holds 18,301,266 shares, accounting for 26.72% of the total shares[25] - The second largest shareholder, Bianjing, holds 13,596,309 shares, accounting for 19.85% of the total shares[25] - The top ten shareholders collectively hold 47,663,280 shares, which is 69.60% of the total shares[25] Commitments and Guarantees - The company has provided guarantees totaling 27,900,000 CNY for loans, with a remaining guarantee balance of 26,900,000 CNY[31] - The company applied for a loan of 9 million CNY from China Everbright Bank, with a guarantee provided by a related party[32] - The company applied for a loan of 5 million CNY from CITIC Bank, with a guarantee provided by the actual controller[32] - The actual controller has committed to not occupying company funds since February 2016, and this commitment is currently being fulfilled[34] - The company has established internal control measures to prevent fund occupation or asset transfer by shareholders and related parties[36] Compliance and Regulatory Matters - The company guarantees that its issuance application documents do not contain false records or misleading statements, and will initiate a share buyback if such issues are identified[39] - The company will disclose specific reasons for any failure to fulfill commitments in a timely manner[39] - The company will ensure compliance with relevant laws and regulations in handling any non-fulfillment of commitments[39] - The company will publicly disclose reasons for any failure to fulfill commitments and apologize to shareholders and the public[38]

Financial Performance - The company achieved a revenue of 216.08 million yuan in 2022, representing a year-on-year increase of 21.6% compared to 2021[14]. - The company's operating revenue for 2022 was ¥216,082,516.98, representing a year-over-year increase of 21.02% compared to ¥178,544,464.08 in 2021[31]. - Net profit reached 41.01 million yuan, reflecting a year-on-year growth of 17.33%[53]. - The net profit attributable to shareholders for 2022 was ¥41,013,230.25, which is a 17.33% increase from ¥34,956,681.11 in 2021[31]. - The total assets at the end of 2022 reached ¥433,992,572.72, marking an 80.96% increase from ¥239,830,757.53 at the end of 2021[33]. - The company's net assets attributable to shareholders increased by 190.37% to ¥281,951,875.27 in 2022 from ¥97,102,408.23 in 2021[33]. - The gross profit margin for 2022 was 47.13%, down from 50.72% in 2021[31]. - The cash flow from operating activities for 2022 was ¥48,321,113.32, a decrease of 9.74% from ¥53,538,177.03 in 2021[35]. - The company's cash and cash equivalents increased to ¥178.41 million, a growth of 747.60% compared to ¥21.05 million in the previous year, primarily due to funds raised from a public offering of shares[63]. Accounts Receivable and Risks - The accounts receivable for 2022 amounted to 91.89 million yuan, which is an increase from 49.66 million yuan in 2021, indicating a rising trend in credit sales[14]. - The company reported a significant increase in accounts receivable as a percentage of revenue, rising from 27.81% in 2021 to 42.52% in 2022, indicating potential cash flow risks[14]. - Accounts receivable rose to ¥58.56 million, reflecting a 134.34% increase from ¥24.99 million, attributed to slower payment collection from downstream food and pharmaceutical enterprises[63]. - The company faces risks related to technological innovation, including potential project failures and market acceptance issues[13]. - The company has implemented appropriate internal controls related to accounts receivable impairment, ensuring accurate financial reporting[119]. Corporate Structure and Governance - The company maintains a concentrated ownership structure, with the actual controllers holding 46.48% of the shares, which may impact corporate governance and decision-making[15]. - The actual controller of the company is Bi Chunguang, with significant shareholders including Bianjing[25]. - The company has established a wholly-owned subsidiary, Liaoning Dianguan Technology Co., Ltd., with a registered capital of ¥10 million, aimed at increasing production capacity for food and pharmaceutical packaging equipment[97]. - The company has committed to improving its governance structure and attracting professional talent to enhance sustainable development capabilities[131]. Innovation and R&D - The company established a research and innovation mechanism focusing on customer and market needs, resulting in 37 authorized patents, including 10 invention patents[44]. - The company has received several awards for its innovative packaging technologies, enhancing its market reputation and brand influence[61]. - The company has developed new products such as a low-cost cheese filling machine and a fully automated packaging line, expected to enhance market competitiveness[109]. - The company is collaborating with Dalian University of Technology on key technology research for cheese filling machines, aiming for industrial application[110]. - The company has established partnerships with research institutions and universities to mitigate risks associated with single-mode R&D failures[134]. Market Position and Strategy - The company specializes in high-flexibility intelligent packaging equipment, focusing on the pharmaceutical and food sectors[24]. - The packaging equipment market is projected to grow from 917 billion USD in 2019 to 1.05 trillion USD by 2024, indicating significant market potential[57]. - The company is positioned in a rapidly growing mid-to-high-end pharmaceutical equipment market, with domestic equipment expected to replace imports[127]. - The company’s future strategy includes focusing on technological innovation and expanding into upstream and downstream industries within the packaging equipment sector[130]. Shareholder Commitments and Transactions - The company has committed to measures to compensate for dilution of immediate returns, with actions taken to address this issue since May 2022[161]. - The controlling shareholders committed to not interfere with the company's management or misappropriate company interests, ensuring that their actions align with the company's profit distribution policies[164]. - The company has committed to publicly disclose any failure to fulfill commitments and apologize to shareholders and the public[166]. - The company has outlined specific measures to ensure that related party transactions are necessary for its operational development and do not harm the interests of other shareholders[166]. Tax Benefits and Financial Incentives - The company received a tax benefit of 5.51 million yuan in 2022, accounting for 11.54% of the total profit, highlighting the importance of tax incentives to profitability[14]. - The company has received a tax reduction on corporate income tax from 25% to 15% due to its recognition as a high-tech enterprise[101]. - In 2022, the company enjoyed a tax benefit of 5.5096 million yuan, accounting for 11.54% of total profit, but risks exist if tax policies change after the expiration of high-tech enterprise certification[139].

Financial Performance - The company's total revenue for 2022 reached CNY 217.43 million, representing a year-on-year increase of 21.78%[4] - Net profit attributable to shareholders was CNY 42.89 million, up 22.69% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 38.62 million, reflecting a growth of 16.11%[4] - Basic earnings per share increased to CNY 0.82, a rise of 22.69% year-on-year[4] Assets and Equity - Total assets at the end of the reporting period amounted to CNY 434.56 million, marking an 81.19% increase from the beginning of the year[4] - Shareholders' equity attributable to the company surged to CNY 283.83 million, a significant increase of 192.30%[4] - The company raised CNY 144 million through the public issuance of 16 million shares on December 16, 2022, contributing to the growth in total assets and equity[6] Revenue Sources and Cost Management - Revenue from high-flexibility intelligent packaging production lines grew by 72.78% year-on-year, contributing to the overall revenue increase[6] - The company reduced its sales expenses related to large-scale exhibitions by 66.13% due to pandemic-related cancellations[6] - Financial costs decreased by 24.90% as the company repaid high-interest bank loans, leading to a reduction in short-term borrowings[6]